ArticleJournal of patient-reported outcomes2025
Meaningful changes in physical function and pain in patients with knee osteoarthritis.
Article in Journal of patient-reported outcomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predicting Long-Term Pain Resilience in Knee Osteoarthritis: An Osteoarthritis Initiative Nomogram.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThis study aims to establish meaningful within-person change (MWPC) thresholds for the Total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC®), its Physical Function (PF) subscale, and the Visual Analog Scale (VAS) for Pain, in patients with knee osteoarthritis (OA). A secondary objective is to evaluate the effectiveness of a single injection of autologous culture-expanded adipose tissue-derived mesenchymal stem cells (ADMSCs) using these thresholds. METHODOLOGY: The study included 252 patients with knee OA enrolled in a clinical trial. An anchor-based predictive modeling approach, using KOOS-12, SF-36, and IKDC scores with literature-based cut-offs, was applied to determine MWPC thresholds for WOMAC and VAS Pain. MWPC thresholds were derived from both the ADMSCs injection and Control (autoserum) groups at 3- and 6-month follow-ups. Treatment effectiveness was assessed by comparing MWPC range with between-group differences and within-person changes.
resultsMWPC thresholds were identified as follows: 5–17 points for WOMAC Total, 4–12 points for WOMAC PF, and 8–14 points for VAS Pain (all on 0–100 scales). The adjusted differences between the ADMSCs injection and Control (autoserum) groups of all three measures (3 months: WOMAC Total 5.9, WOMAC Function 4.2, VAS Pain 8.6; 6 months: WOMAC Total 9.3, WOMAC Function 6.5, VAS Pain 11.7) were within each corresponding MWPC threshold range.
conclusionsThe proposed MWPC thresholds could be beneficial for healthcare professionals as a tool to identify meaningful change in physical function and pain in response to treatment and evaluate the meaningfulness of treatment benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.